Best Agrolife Ltd (BESTAGRO)

Chemicals · Agro Chemicals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹17.11 ↓ 32.95% (1Y)

🎯 Key Takeaways

Best Agrolife Ltd is transitioning from a low-margin, cyclical agrochemical producer to a higher-margin, innovation-driven specialty chemical company, evidenced by a strategic shift toward patented products now contributing over 60% of branded sales and driving disproportionate profitability gains. The company is in a growth phase, supported by international expansion and product differentiation, though scale and margin sustainability remain key focus areas.
Revenue grew 154.5% QoQ to ₹396 in Q1FY27.
⚠️ Monsoon dependency remains a structural risk, as demand volatility directly impacts revenue visibility despite management’s optimism about crop prospe

Market Cap

₹607

P/E Ratio

1.1

P/B Ratio

0.84

ROE

4.1%

ROCE

7.9%

Debt/Equity

0.65

Div Yield

0.58%

Promoter

50.4%

✨ Ask AI About BESTAGRO 📊 Interactive Charts

📖 The Story

Best Agrolife Ltd is transitioning from a low-margin, cyclical agrochemical producer to a higher-margin, innovation-driven specialty chemical company, evidenced by a strategic shift toward patented products now contributing over 60% of branded sales and driving disproportionate profitability gains. The company is in a growth phase, supported by international expansion and product differentiation, though scale and margin sustainability remain key focus areas.

📰 What's Happening

In Q1 FY27, revenue grew 4% YoY to Rs 396 crores, with PAT doubling to Rs 41 crores and EBITDA surging 70% to Rs 78 crores, driven by a shift toward patented products that now account for 64-65% of branded sales (up from 45% YoY). Gross margins expanded to 37% from 29% YoY, supported by favorable product mix, selective price hikes, and cost optimization. Management highlighted strong demand for new launches like Fluzam and Cubax PowerExtra, targeting 10-15% CAGR over 3-4 years and sustainable EBITDA margins of 13-14%. International expansion into Nepal, Thailand, Vietnam, and Mexico is progressing, and CAPEX is currently on hold, with future funding potentially via QIP.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	517	203	156	396
Operating Profit	67	-7	-37	68
OPM %	13.0%	-3.3%	-24.0%	17.1%
Net Profit	39	-13	-37	41
EPS	₹16.46	₹-0.36	₹-1.05	₹1.15

The company’s financial trajectory shows a clear inflection point: after years of volatility, including losses in Dec 2025 and Mar 2026, profitability has sharply improved in Q1 FY27 with PAT margin rising to 11% from 5% and EBITDA margin to 20% from 12%. This turnaround is not driven by volume growth but by structural margin expansion and inventory reduction to Rs 700 crores from Rs 1,000 crores. Revenue growth remains modest at 4% YoY, but profitability gains are material and sustainable, reflecting successful product mix optimization and operational efficiency.

🔮 Management Outlook & What's Next

Management expects patented products to contribute 75-80% of branded sales within 2-3 years, underpinning 10-15% annual revenue CAGR and sustainable EBITDA margins of 13-14%. They cite improving monsoon conditions, strong crop prospects, and adoption of differentiated crop protection solutions as tailwinds. CAPEX is on hold, with future funding potentially through a qualified institutional placement (QIP), indicating a capital-light growth strategy focused on profitability and working capital discipline rather than aggressive expansion.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	24	24	24	35
Reserves	732	696	748	696
Borrowings	578	467	436	442
Total Liabilities	2,403	1,950	1,963	1,686
Fixed Assets	220	374	228	228
Investments	0	1	1	1
Total Assets	2,403	1,950	1,963	1,686

The balance sheet reflects a company shifting from capital-intensive operations to a more efficient, asset-light model. Total assets declined slightly to Rs 1,686 crores from Rs 1,963 crores YoY, while equity increased to Rs 35 crores from Rs 24 crores, driven by reserves. Borrowings remain stable at around Rs 440 crores, indicating controlled leverage (D/E of 0.65). The reduction in inventory and stable debt levels suggest improved working capital management and a focus on cash flow generation over asset buildup.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+228
Investing	-29
Financing	-199
Net Cash Flow	-0

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	50.4%	50.4%	50.4%
FII	5.6%	5.5%	5.6%
DII	2.1%	2.1%	2.1%
Public	35.2%	35.8%	35.7%
# Shareholders	38,180	68,254	66,662

Institutional investor interest remains low, with FII holding steady at 5.52-5.63% over the past three quarters, and DII at approximately 2.11-2.13%. Promoter holding is stable at 50.44%. The number of public shareholders has increased to 66,662 from 38,180, indicating broader retail participation. There is no evidence of significant accumulation or exit by institutions, suggesting limited institutional conviction despite improving fundamentals.

⚖️ Peer Comparison — Agro Chemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
UPL	47,750	23.4	11.4%	6.7%	0.64
PIIND	36,230	31.1	13.3%	10.4%	0.02
SUMICHEM	25,674	44.3	23.1%	17.1%	0.00
BAYERCROP	17,940	371.7	3.3%	1.2%	0.00
SHARDACROP	7,113	11.4	25.8%	20.0%	0.00
DHANUKA	4,409	15.1	27.5%	21.2%	0.03
RALLIS	4,032	24.6	12.9%	9.7%	0.03
NACLIND	3,948	337.1	6.0%	1.8%	0.44
BHAGCHEM	3,496	127.2	6.1%	3.9%	0.33
GSPCROP	2,890	25.3	22.5%	21.9%	0.66

🔗 Peer Stock Analyses

UPL PIIND SUMICHEM BAYERCROP SHARDACROP

⚠️ Risk Factors

1. Monsoon dependency remains a structural risk, as demand volatility directly impacts revenue visibility despite management’s optimism about crop prospects. 2. International expansion into niche markets may face execution and regulatory challenges, limiting scalability. 3. The shift to patented products is progressing but not yet dominant (64% contribution), and sustaining margin gains requires continuous innovation and IP protection. 4. CAPEX is on hold, which may constrain long-term growth if external funding conditions deteriorate or market opportunities accelerate.

📋 Recent Filings

🧠 Analyst's Read

Best Agrolife is executing a credible turnaround driven by product innovation and margin expansion, but the transition is still early — profitability gains are real but need to be sustained and scaled. Investors should watch for consistent margin improvement, faster adoption of patented products beyond 65%, and clearer signs of international revenue contribution to validate the growth narrative.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on BESTAGRO

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when BESTAGRO files new disclosures

Track BESTAGRO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track BESTAGRO — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd